IGC Pharma, Inc.: Form 10-Q for the period ended Sep 30, 2024
Filed with the SEC on Nov 12, 2024 and accepted by EDGAR at Nov 12, 2024, 21:04 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2024-07-01 to 2024-09-30 | $412.0k | us-gaap:Revenues |
| Revenue | 6 months2024-04-01 to 2024-09-30 | $684.0k | us-gaap:Revenues |
| Cost of revenue | 3 months2024-07-01 to 2024-09-30 | $214.0k | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months2024-04-01 to 2024-09-30 | $323.0k | us-gaap:CostOfRevenue |
| Gross profit | 3 months2024-07-01 to 2024-09-30 | $198.0k | us-gaap:GrossProfit |
| Gross profit | 6 months2024-04-01 to 2024-09-30 | $361.0k | us-gaap:GrossProfit |
| Research and development | 3 months2024-07-01 to 2024-09-30 | $917.0k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2024-04-01 to 2024-09-30 | $1.8m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2024-07-01 to 2024-09-30 | $1.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2024-04-01 to 2024-09-30 | $2.7m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2024-07-01 to 2024-09-30 | −$1.8m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2024-04-01 to 2024-09-30 | −$4.2m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2024-07-01 to 2024-09-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2024-04-01 to 2024-09-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2024-07-01 to 2024-09-30 | −$1.7m | us-gaap:NetIncomeLoss |
| Net income | 6 months2024-04-01 to 2024-09-30 | −$4.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2024-07-01 to 2024-09-30 | −$0.02 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2024-04-01 to 2024-09-30 | −$0.06 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2024-07-01 to 2024-09-30 | −$0.02 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2024-04-01 to 2024-09-30 | −$0.06 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2024-07-01 to 2024-09-30 | 76,007,129 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2024-04-01 to 2024-09-30 | 74,419,059 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2024-04-01 to 2024-09-30 | −$2.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2024-04-01 to 2024-09-30 | $67.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2024-09-30 | $1.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-09-30 | $4.3m | us-gaap:AssetsCurrent |
| Total assets | At period end2024-09-30 | $10.4m | us-gaap:Assets |
| Current liabilities | At period end2024-09-30 | $2.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-09-30 | $3.0m | us-gaap:Liabilities |
| Long-term debt | At period end2024-09-30 | $135.0k | us-gaap:LongTermDebtNoncurrent |
| Short-term borrowings | At period end2024-09-30 | $3.0k | us-gaap:ShortTermBorrowings |
| Shareholders' equity | At period end2024-09-30 | $7.4m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001185185-24-001096. Last ingested by Listed: Oct 24, 2026, 15:11 ET. Listed shows no prices and gives no investment advice.